Skip to content

Xeris Pharmaceuticals

US · XERS #2862 by market cap Listed 2018
16.97 +0.35 +2.11%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:57

Valuation each multiple against its own 5-year range

P/B ratio 62.40 Expensive vs history 86th percentile
5-year average -99.71 · #67 of 68 in Drug Manufacturers - Specialty & Generic
P/E ratio -617.04 Cheap vs history 0th percentile
5-year average 60.12 · forward 48.74
P/S ratio 8.27 Expensive vs history 97th percentile
5-year average 3.60 · forward 6.06 · #65 of 78 in Drug Manufacturers - Specialty & Generic

Vs. peers Drug Manufacturers - Specialty & Generic

Company Market cap P/E (TTM) P/B Div yield
Xeris Pharmaceuticals (XERS) 3.10B -628.52 63.56 0.00%
Takeda Pharmaceutical (TAK) 69.76B 311.00 1.50 1.44%
Teva Pharmaceutical Industries (TEVA) 45.77B 91.23 5.74 0.00%
Haleon (HLN) 39.76B 19.14 1.85 2.09%
Zoetis (ZTS) 32.14B 13.34 9.73 2.64%
United Therapeutics (UTHR) 23.63B 20.94 3.76 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★☆☆☆ Fair value13.26 Economic moatNone UncertaintyHigh

Trading 21.8% above Morningstar's fair value estimate.

Fair value

Xeris Biopharma Holdings Inc receives a 2-star quantitative star rating, illustrating our stance that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 26% premium over our quantitative fair value estimate of $13.26 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The company's valuation metrics weaken our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 1.8%, which sits in the bottom 10% compared with peers globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are expensive.

The company's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 2.0%, a core component of profitability, lies in the bottom 40% globally. The earnings generated by the company relative to its share price is concerning, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:57:17 · For reference only, not investment advice and not tailored to your situation.

Xeris Pharmaceuticals discussion 0 comments

Add a comment